Skip to main content
Top
Published in: International Urology and Nephrology 5/2018

01-05-2018 | Urology - Original Paper

Effects of combined treatment of tadalafil and tamsulosin on bladder dysfunction via the inhibition of afferent nerve activities in a rat model of bladder outlet obstruction

Authors: Akira Furuta, Yasuyuki Suzuki, Taro Igarashi, Yusuke Koike, Shin Egawa, Naoki Yoshimura

Published in: International Urology and Nephrology | Issue 5/2018

Login to get access

Abstract

Purpose

To investigate the effects of combined treatment of tadalafil (a phosphodiesterase-5 inhibitor) and tamsulosin (an α1-adrenoceptor antagonist) on bladder dysfunction in a rat model of bladder outlet obstruction (BOO).

Methods

Cystometry was performed in conscious female BOO rats 6 weeks after partially ligation of the urethra. Either tadalafil (0.03, 0.1 and 0.3 mg/kg) or tamsulosin (0.001, 0.003 and 0.01 mg/kg) was cumulatively applied intravenously at 30-min intervals to examine changes in cystometric parameters and blood pressures. Changes in cystometric parameters and blood pressures were also checked when tadalafil (0.3 mg/kg), tamsulosin (0.003 mg/kg) or both were intravenously applied.

Results

In BOO rats, application of either tadalafil (0.3 mg/kg) or tamsulosin (0.003, 0.01 mg/kg) alone significantly increased threshold pressures and intercontraction intervals whereas there were no significant changes in other cystometric parameters. In addition, because a significant reduction in blood pressures was detected after the administration of tamsulosin (0.01 mg/kg), tamsulosin at a lower dose (0.003 mg/kg) was used for the combined treatment. The combination therapy of tadalafil and tamsulosin induced a significantly larger rate of increase in intercontraction intervals (1.7 times) compared with monotherapy of either drug (1.3 times each) although the combined therapy did not affect blood pressures.

Conclusions

These results suggest that the combination therapy of tadalafil and tamsulosin can induce the additive inhibitory effects on urinary frequency compared with monotherapy, more likely via inhibition of the afferent limb of micturition reflex rather than the efferent function as evidenced by the increases in threshold pressures and intercontraction intervals without affecting bladder contractile function.
Literature
1.
go back to reference Homma Y, Gotoh M, Yokoyama O, Masumori N, Kawauchi A et al (2011) Outline of JUA clinical guidelines for benign prostatic hyperplasia. Int J Urol 18:741–756CrossRefPubMed Homma Y, Gotoh M, Yokoyama O, Masumori N, Kawauchi A et al (2011) Outline of JUA clinical guidelines for benign prostatic hyperplasia. Int J Urol 18:741–756CrossRefPubMed
2.
go back to reference Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S et al (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64:118–140CrossRefPubMed Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S et al (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64:118–140CrossRefPubMed
3.
4.
go back to reference Yokoyama O, Igawa Y, Takeda M, Yamaguchi T, Murakami M et al (2015) Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action. Ther Adv Urol 7:249–264CrossRefPubMedPubMedCentral Yokoyama O, Igawa Y, Takeda M, Yamaguchi T, Murakami M et al (2015) Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action. Ther Adv Urol 7:249–264CrossRefPubMedPubMedCentral
5.
go back to reference Aizawa N, Sugiyama R, Ichihara K, Fujimura T, Fukuhara H et al (2016) Functional roles of bladder alpha1-adrenoceptors in the activation of single-unit primary bladder afferent activity in rats. BJU Int 117:993–1001CrossRefPubMed Aizawa N, Sugiyama R, Ichihara K, Fujimura T, Fukuhara H et al (2016) Functional roles of bladder alpha1-adrenoceptors in the activation of single-unit primary bladder afferent activity in rats. BJU Int 117:993–1001CrossRefPubMed
6.
go back to reference Minagawa T, Aizawa N, Igawa Y, Wyndaele JJ (2012) Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves. BJU Int 110:E259–E266CrossRefPubMed Minagawa T, Aizawa N, Igawa Y, Wyndaele JJ (2012) Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves. BJU Int 110:E259–E266CrossRefPubMed
7.
go back to reference Goi Y, Tomiyama Y, Nomiya M, Sagawa K, Aikawa K et al (2013) Effects of silodosin, a selective alpha1A-adrenoceptor antagonist, on bladder blood flow and bladder function in a rat model of atherosclerosis induced chronic bladder ischemia without bladder outlet obstruction. J Urol 190:1116–1122CrossRefPubMed Goi Y, Tomiyama Y, Nomiya M, Sagawa K, Aikawa K et al (2013) Effects of silodosin, a selective alpha1A-adrenoceptor antagonist, on bladder blood flow and bladder function in a rat model of atherosclerosis induced chronic bladder ischemia without bladder outlet obstruction. J Urol 190:1116–1122CrossRefPubMed
8.
go back to reference Yoshinaga R, Kawai Y, Oka M, Fuchikami C, Oyama T (2015) Effect of a single treatment with tadalafil on blood flow in lower urinary tract tissues in rat models of bladder overdistension/emptying and abdominal aorta clamping/release. Eur J Pharmacol 754:92–97CrossRefPubMed Yoshinaga R, Kawai Y, Oka M, Fuchikami C, Oyama T (2015) Effect of a single treatment with tadalafil on blood flow in lower urinary tract tissues in rat models of bladder overdistension/emptying and abdominal aorta clamping/release. Eur J Pharmacol 754:92–97CrossRefPubMed
9.
go back to reference Nomiya M, Burmeister DM, Sawada N, Campeau L, Zarifpour M et al (2013) Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia. J Urol 189:754–761CrossRefPubMed Nomiya M, Burmeister DM, Sawada N, Campeau L, Zarifpour M et al (2013) Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia. J Urol 189:754–761CrossRefPubMed
10.
go back to reference Singh DV, Mete UK, Mandal AK, Singh SK (2014) A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil versus tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. J Sex Med 11:187–196CrossRefPubMed Singh DV, Mete UK, Mandal AK, Singh SK (2014) A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil versus tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. J Sex Med 11:187–196CrossRefPubMed
11.
go back to reference Angulo J, Cuevas P, Fernandez A, La Fuente JM, Allona A et al (2012) Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. J Sex Med 9:2293–2306CrossRefPubMed Angulo J, Cuevas P, Fernandez A, La Fuente JM, Allona A et al (2012) Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. J Sex Med 9:2293–2306CrossRefPubMed
12.
go back to reference Kita M, Yunoki T, Takimoto K, Miyazato M, Kita K et al (2010) Effects of bladder outlet obstruction on properties of Ca2+-activated K+ channels in rat bladder. Am J Physiol Regul Integr Comp Physiol 298:R1310–R1319CrossRefPubMedPubMedCentral Kita M, Yunoki T, Takimoto K, Miyazato M, Kita K et al (2010) Effects of bladder outlet obstruction on properties of Ca2+-activated K+ channels in rat bladder. Am J Physiol Regul Integr Comp Physiol 298:R1310–R1319CrossRefPubMedPubMedCentral
13.
go back to reference Nagase K, Ito H, Aoki Y, Tanase K, Akino H et al (2011) Co-administration of an alpha(1)-blocker improves the efficacy and safety of antimuscarinic agents in rats with detrusor overactivity. Int J Urol 18:836–843CrossRefPubMed Nagase K, Ito H, Aoki Y, Tanase K, Akino H et al (2011) Co-administration of an alpha(1)-blocker improves the efficacy and safety of antimuscarinic agents in rats with detrusor overactivity. Int J Urol 18:836–843CrossRefPubMed
14.
go back to reference Furuta A, Suzuki Y, Kimura S, Koike Y, Egawa S et al (2016) Combination therapy with beta3 -adrenoceptor agonists and muscarinic acetylcholine receptor antagonists: efficacy in rats with bladder overactivity. Int J Urol 23:425–430CrossRefPubMed Furuta A, Suzuki Y, Kimura S, Koike Y, Egawa S et al (2016) Combination therapy with beta3 -adrenoceptor agonists and muscarinic acetylcholine receptor antagonists: efficacy in rats with bladder overactivity. Int J Urol 23:425–430CrossRefPubMed
15.
go back to reference Yoshimura N, Chancellor MB (2006) Physiology and pharmacology of the bladder and urethra, chapter 56. In: Wein AJ (ed) Cambell–Walsh urology, vol 9. B. Saunders Elserion, Philadelphia, pp 1922–1972 Yoshimura N, Chancellor MB (2006) Physiology and pharmacology of the bladder and urethra, chapter 56. In: Wein AJ (ed) Cambell–Walsh urology, vol 9. B. Saunders Elserion, Philadelphia, pp 1922–1972
16.
go back to reference Masuda H, Okuno T, Suzuki M, Kihara K, Goto M et al (2002) Different distribution of nitric oxide synthase and soluble guanylyl cyclase activities in the detrusor and proximal urethra of the rabbit. J Urol 168:2286–2290CrossRefPubMed Masuda H, Okuno T, Suzuki M, Kihara K, Goto M et al (2002) Different distribution of nitric oxide synthase and soluble guanylyl cyclase activities in the detrusor and proximal urethra of the rabbit. J Urol 168:2286–2290CrossRefPubMed
17.
go back to reference Buono R, Briganti A, Freschi M, Villa L, La Croce G et al (2014) Silodosin and tadalafil have synergistic inhibitory effects on nerve-mediated contractions of human and rat isolated prostates. Eur J Pharmacol 744:42–51CrossRefPubMed Buono R, Briganti A, Freschi M, Villa L, La Croce G et al (2014) Silodosin and tadalafil have synergistic inhibitory effects on nerve-mediated contractions of human and rat isolated prostates. Eur J Pharmacol 744:42–51CrossRefPubMed
18.
go back to reference Yoshida M, Akaike T, Inadome A, Takahashi W, Seshita H et al (1998) The possible effect of nitric oxide on relaxation and noradrenaline release in the isolated rabbit urethra. Eur J Pharmacol 357:213–219CrossRefPubMed Yoshida M, Akaike T, Inadome A, Takahashi W, Seshita H et al (1998) The possible effect of nitric oxide on relaxation and noradrenaline release in the isolated rabbit urethra. Eur J Pharmacol 357:213–219CrossRefPubMed
19.
go back to reference MacDiarmid SA, Hill LA, Volinn W, Hoel G (2010) Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. Urology 75:520–525CrossRefPubMed MacDiarmid SA, Hill LA, Volinn W, Hoel G (2010) Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. Urology 75:520–525CrossRefPubMed
Metadata
Title
Effects of combined treatment of tadalafil and tamsulosin on bladder dysfunction via the inhibition of afferent nerve activities in a rat model of bladder outlet obstruction
Authors
Akira Furuta
Yasuyuki Suzuki
Taro Igarashi
Yusuke Koike
Shin Egawa
Naoki Yoshimura
Publication date
01-05-2018
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 5/2018
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-018-1835-8

Other articles of this Issue 5/2018

International Urology and Nephrology 5/2018 Go to the issue

Response - Urology Letter

Re: Letter to the editor

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine